Published in Am J Pathol on September 01, 1997
Endothelin-1 induces alveolar epithelial-mesenchymal transition through endothelin type A receptor-mediated production of TGF-beta1. Am J Respir Cell Mol Biol (2007) 2.50
Endothelin-1 promotes myofibroblast induction through the ETA receptor via a rac/phosphoinositide 3-kinase/Akt-dependent pathway and is essential for the enhanced contractile phenotype of fibrotic fibroblasts. Mol Biol Cell (2004) 2.29
Constitutive ALK5-independent c-Jun N-terminal kinase activation contributes to endothelin-1 overexpression in pulmonary fibrosis: evidence of an autocrine endothelin loop operating through the endothelin A and B receptors. Mol Cell Biol (2006) 1.87
Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities. Nat Rev Rheumatol (2011) 1.82
Systemic sclerosis associated pulmonary hypertension: improved survival in the current era. Heart (2005) 1.73
How does endothelial cell injury start? The role of endothelin in systemic sclerosis. Arthritis Res Ther (2007) 1.40
Role of endothelin-1 in lung disease. Respir Res (2001) 1.36
Myofibroblasts: trust your heart and let fate decide. J Mol Cell Cardiol (2013) 1.25
Endothelin-1 and transforming growth factor-beta1 independently induce fibroblast resistance to apoptosis via AKT activation. Am J Respir Cell Mol Biol (2009) 1.20
Soluble adhesion molecules (sVCAM-1, sE-selectin), vascular endothelial growth factor (VEGF) and endothelin-1 in patients with systemic sclerosis: relationship to organ systemic involvement. Clin Rheumatol (2004) 1.16
Inhibition of endothelin receptors in the treatment of pulmonary arterial hypertension: does selectivity matter? Eur Heart J (2008) 1.10
Inhibition of focal adhesion kinase prevents experimental lung fibrosis and myofibroblast formation. Arthritis Rheum (2012) 1.06
Autoantibodies to angiotensin and endothelin receptors in systemic sclerosis induce cellular and systemic events associated with disease pathogenesis. Arthritis Res Ther (2014) 0.94
dsRNA activation of endothelin-1 and markers of vascular activation in endothelial cells and fibroblasts. Ann Rheum Dis (2010) 0.92
Biomarkers in systemic sclerosis. Biomark Med (2010) 0.90
BMPR2 mutation alters the lung macrophage endothelin-1 cascade in a mouse model and patients with heritable pulmonary artery hypertension. Am J Physiol Lung Cell Mol Physiol (2010) 0.89
Systemic vasculopathy with altered vasoreactivity in a transgenic mouse model of scleroderma. Arthritis Res Ther (2010) 0.88
Localization of endothelin receptors in bleomycin-induced pulmonary fibrosis in the rat. Histochem Cell Biol (2004) 0.87
Role of host genetics in fibrosis. Fibrogenesis Tissue Repair (2009) 0.86
The role of endothelin-1 in the pathogenesis of idiopathic pulmonary fibrosis. BioDrugs (2010) 0.86
Clinical trials in systemic sclerosis: lessons learned and outcomes. Arthritis Res Ther (2007) 0.84
T cell repertoire in patients with stable scleroderma. Clin Exp Immunol (2005) 0.82
Urotensin-II in systemic sclerosis: a new peptide in pathogenesis. Clin Rheumatol (2011) 0.81
Angiotensin receptor type 1 and endothelin receptor type A on immune cells mediate migration and the expression of IL-8 and CCL18 when stimulated by autoantibodies from systemic sclerosis patients. Arthritis Res Ther (2014) 0.81
Systemic sclerosis: current concepts in pathogenesis and therapeutic aspects of dermatological manifestations. Indian J Dermatol (2013) 0.81
Endothelial to mesenchymal transition (EndoMT) in the pathogenesis of Systemic Sclerosis-associated pulmonary fibrosis and pulmonary arterial hypertension. Myth or reality? Matrix Biol (2016) 0.80
The current state of biomarkers in systemic sclerosis. Curr Rheumatol Rep (2010) 0.80
Interstitial lung disease in systemic sclerosis: current and future treatment. Rheumatol Int (2017) 0.78
Patient considerations and drug selection in the treatment of idiopathic pulmonary fibrosis. Ther Clin Risk Manag (2016) 0.77
Circulating biomarkers of interstitial lung disease in systemic sclerosis. Int J Rheumatol (2012) 0.77
The cytokine language of monocytes and macrophages in systemic sclerosis. Arthritis Res Ther (2010) 0.77
Vascular dysfunction by myofibroblast activation in patients with idiopathic pulmonary fibrosis and prognostic significance. Braz J Med Biol Res (2012) 0.75
Endothelin-1 in systemic sclerosis. Indian Dermatol Online J (2012) 0.75
Knockout of endothelin type B receptor signaling attenuates bleomycin-induced skin sclerosis in mice. Arthritis Res Ther (2016) 0.75
Isolated pulmonary veno-occlusive disease and pulmonary arterial thrombosis in systemic sclerosis - a lethal combination. Int Med Case Rep J (2010) 0.75
Searching for a good model for systemic sclerosis: the molecular profile and vascular changes occurring in UCD-200 chickens strongly resemble the early phase of human systemic sclerosis. Arch Med Sci (2016) 0.75
Gas exchange and pulmonary hypertension following acute pulmonary thromboembolism: has the emperor got some new clothes yet? Pulm Circ (2014) 0.75
Pulmonary Arterial Hypertension-A Deadly Complication of Systemic Sclerosis. J Clin Rheumatol Musculoskelet Med (2010) 0.75
Is macitentan not a treatment option for digital ulcers in systemic sclerosis? Ann Transl Med (2016) 0.75
Endothelin-1, α-Klotho, 25(OH) Vit D levels and severity of disease in scleroderma patients. Rheumatol Int (2017) 0.75
Angiogenesis Dysregulation in the Pathogenesis of Systemic Sclerosis. Biomed Res Int (2017) 0.75
Expression of the CD34 gene in vascular endothelial cells. Blood (1990) 4.41
Endothelins: molecular biology, biochemistry, pharmacology, physiology, and pathophysiology. Pharmacol Rev (1994) 4.19
Hypoxia induces endothelin gene expression and secretion in cultured human endothelium. J Clin Invest (1991) 3.18
Circulating endothelin-1 levels in systemic sclerosis subsets--a marker of fibrosis or vascular dysfunction? J Rheumatol (1994) 2.76
Exaggerated spontaneous release of platelet-derived growth factor by alveolar macrophages from patients with idiopathic pulmonary fibrosis. N Engl J Med (1987) 2.62
Endothelins. N Engl J Med (1995) 2.52
Pathogenesis of systemic sclerosis: a vascular hypothesis. Semin Arthritis Rheum (1975) 2.30
The endothelin family of peptides: local hormones with diverse roles in health and disease? Clin Sci (Lond) (1993) 2.18
Molecular characterization of endothelin receptors. Trends Pharmacol Sci (1992) 2.04
Cloning and functional expression of a vascular smooth muscle endothelin 1 receptor. Proc Natl Acad Sci U S A (1991) 1.93
Endothelins, peptides with potent vasoactive properties, are produced by human macrophages. J Exp Med (1990) 1.60
Immunohistochemical localization of transforming growth factor-beta 1 in the lungs of patients with systemic sclerosis, cryptogenic fibrosing alveolitis and other lung disorders. Histopathology (1994) 1.54
Expression of endothelin-1 in lungs of patients with cryptogenic fibrosing alveolitis. Lancet (1993) 1.42
Structural features of interstitial lung disease in systemic sclerosis. Am Rev Respir Dis (1991) 1.41
Endothelin, an endothelial-dependent vasoconstrictor in scleroderma. Enhanced production and profibrotic action. Arthritis Rheum (1991) 1.36
Epithelial cell-fibroblast interactions in lung injury and repair. Am J Pathol (1990) 1.35
Presence of non-selective type of endothelin receptor on vascular endothelium and its linkage to vasodilation. FEBS Lett (1991) 1.33
Significance of plasma endothelin-1 levels in patients with systemic sclerosis. J Rheumatol (1992) 1.32
Endothelin receptors and calcium signaling. FASEB J (1995) 1.30
Different distribution of endothelin receptor subtypes in pulmonary tissues revealed by the novel selective ligands BQ-123 and [Ala1,3,11,15]ET-1. Biochem Biophys Res Commun (1992) 1.24
Autoradiographic localization of endothelin-1 binding sites in the cardiovascular and respiratory systems. J Cardiovasc Pharmacol (1989) 1.21
Functional analysis of the endothelin-1 gene promoter. Evidence for an endothelial cell-specific cis-acting sequence. J Biol Chem (1990) 1.21
Effects of endothelins on collagen turnover in cardiac fibroblasts. Cardiovasc Res (1993) 1.16
Increased levels of endothelin-1 in bronchoalveolar lavage fluid from patients with systemic sclerosis contribute to fibroblast mitogenic activity in vitro. Am J Respir Cell Mol Biol (1994) 1.16
Regulation of endothelin-1 gene expression by Fos and Jun. J Biol Chem (1991) 1.14
Endothelins and the lung. Am J Respir Crit Care Med (1996) 1.12
Pulmonary involvement in systemic sclerosis: the detection of early changes by thin section CT scan, bronchoalveolar lavage and 99mTc-DTPA clearance. Respir Med (1989) 1.11
Heterogeneity of cell surface endothelin receptors. J Biol Chem (1990) 1.07
Endothelins produced by endothelial cells promote collagen gel contraction by fibroblasts. J Cell Biol (1991) 1.04
Localization of endothelin-1 and its binding sites in scleroderma skin. J Rheumatol (1994) 0.99
The biosynthesis of endothelin-1 by human polymorphonuclear leukocytes. Biochem Biophys Res Commun (1991) 0.99
Endothelin-1 synthesis, receptors, and signal transduction in alveolar epithelium: evidence for an autocrine role. Am J Physiol (1995) 0.97
Receptors for endothelin-1 in asthmatic human peripheral lung. Br J Pharmacol (1995) 0.96
A novel subtype of endothelin receptors. J Biol Chem (1992) 0.96
Down-regulation of endothelin binding sites in rat vascular smooth muscle cells. Am J Hypertens (1990) 0.94
An endothelin-1 mediated autocrine growth loop involved in human renal tubular regeneration. Kidney Int (1995) 0.94
Phorbol ester promotes a sustained down-regulation of endothelin receptors and cellular responses to endothelin in human vascular smooth muscle cells. Biochem Biophys Res Commun (1990) 0.93
Expression of class II major histocompatibility complex antigens on alveolar epithelium in interstitial lung disease: relevance to pathogenesis of idiopathic pulmonary fibrosis. J Clin Pathol (1987) 0.90
Autoradiographic localization of [125I]endothelin binding sites in human blood vessels and coronary tissue: functional correlates. J Cardiovasc Pharmacol (1991) 0.88
Endothelin receptors in cultured adult rat cardiac fibroblasts. Cardiovasc Res (1993) 0.88
Receptor kinetics differ for endothelin-1 and endothelin-2 binding to Swiss 3T3 fibroblasts. Biochem Biophys Res Commun (1990) 0.88
Characterization of endothelin-binding sites in human skin and their regulation in primary Raynaud's phenomenon and systemic sclerosis. J Invest Dermatol (1993) 0.88
1992 International Conference of the American Lung Association and the American Thoracic Society. May 17-20, 1992, Miami Beach, Florida. Abstracts. Am Rev Respir Dis (1992) 0.87
Altered expression of ETB-receptor mRNA in the lung of rats with pulmonary hypertension. J Cardiovasc Pharmacol (1993) 0.84
Endothelin-1-selective binding sites are downregulated by transforming growth factor-beta and upregulated by basic fibroblast growth factor in a vascular smooth muscle-derived cell line. J Cardiovasc Pharmacol (1994) 0.84
Endothelin-1 induces increased fibronectin expression in human bronchial epithelial cells. Biochem Biophys Res Commun (1996) 0.82
Specific binding of endothelin-1 to canine tracheal epithelial cells in culture. Am J Physiol (1995) 0.81
Localization of immunoreactive endothelin and proendothelin in the human lung. Pulm Pharmacol (1992) 0.81
CTGF and SMADs, maintenance of scleroderma phenotype is independent of SMAD signaling. J Biol Chem (2001) 3.28
Echocardiography and pulmonary function as screening tests for pulmonary arterial hypertension in systemic sclerosis. Rheumatology (Oxford) (2004) 3.12
Evaluation of polymerase chain reaction for diagnosis of pneumococcal pneumonia. J Clin Microbiol (1993) 3.04
Family study of the major histocompatibility complex in patients with systemic lupus erythematosus: importance of null alleles of C4A and C4B in determining disease susceptibility. Br Med J (Clin Res Ed) (1983) 2.86
Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis (2003) 2.85
A disease severity scale for systemic sclerosis: development and testing. J Rheumatol (1999) 2.85
Circulating endothelin-1 levels in systemic sclerosis subsets--a marker of fibrosis or vascular dysfunction? J Rheumatol (1994) 2.76
The specificity of fetal IgM: antibody or anti-antibody? Ann N Y Acad Sci (1975) 2.65
The prognostic significance of the histologic pattern of interstitial pneumonia in patients presenting with the clinical entity of cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med (2000) 2.63
Antibody-dependent cell-mediated cytotoxicity to target cells infected with type 1 and type 2 herpes simplex virus. J Immunol (1976) 2.49
European multicentre study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity indexes. Ann Rheum Dis (2001) 2.49
The promise of integrated representative surveys about sexually transmitted diseases and behavior. Sex Transm Dis (1997) 2.44
Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosis. Arthritis Rheum (2010) 2.37
Accuracy of the typical computed tomographic appearances of fibrosing alveolitis. Thorax (1993) 2.33
Association of phenotypic and genotypic characteristics of invasive Streptococcus pyogenes isolates with clinical components of streptococcal toxic shock syndrome. Infect Immun (1993) 2.32
Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions. Ann Rheum Dis (2006) 2.28
Primary Pneumocystis carinii and cytomegalovirus infections. Lancet (1981) 2.23
Nonspecific interstitial pneumonia and usual interstitial pneumonia: comparative appearances at and diagnostic accuracy of thin-section CT. Radiology (2001) 2.20
Evaluation of bias in diagnostic-test sensitivity and specificity estimates computed by discrepant analysis. J Clin Microbiol (1998) 2.14
Scleroderma renal crisis: patient characteristics and long-term outcomes. QJM (2007) 2.14
A histologic pattern of nonspecific interstitial pneumonia is associated with a better prognosis than usual interstitial pneumonia in patients with cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med (1999) 2.08
Role of superoxide dismutase and catalase as determinants of pathogenicity of Nocardia asteroides: importance in resistance to microbicidal activities of human polymorphonuclear neutrophils. Infect Immun (1985) 2.06
Evaluation of nucleic acid amplification tests as reference tests for Chlamydia trachomatis infections in asymptomatic men. J Clin Microbiol (2000) 2.02
Comparison of Doppler echocardiography and right heart catheterization to assess pulmonary hypertension in systemic sclerosis. Br J Rheumatol (1997) 2.00
Genetic mutations in surfactant protein C are a rare cause of sporadic cases of IPF. Thorax (2004) 1.96
Mycophenolate mofetil in diffuse cutaneous systemic sclerosis--a retrospective analysis. Rheumatology (Oxford) (2006) 1.94
Multiple drug-resistant Chlamydia trachomatis associated with clinical treatment failure. J Infect Dis (2000) 1.89
Childhood-onset scleroderma: is it different from adult-onset disease. Arthritis Rheum (1996) 1.85
Imatinib for the treatment of refractory, diffuse systemic sclerosis. Rheumatology (Oxford) (2008) 1.83
Measurement and characterisation of circulating anti-endothelial cell IgG in connective tissue diseases. Clin Exp Immunol (1988) 1.83
Comparison of arbitrarily primed polymerase chain reaction, ribotyping, and monoclonal antibody analysis for subtyping Legionella pneumophila serogroup 1. J Clin Microbiol (1993) 1.82
Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine. Rheumatology (Oxford) (2001) 1.82
BAL findings in idiopathic nonspecific interstitial pneumonia and usual interstitial pneumonia. Eur Respir J (2003) 1.81
A pilot study of the prevalence of chlamydial infection in a national household survey. Sex Transm Dis (1998) 1.78
Immunogenetic prediction of pulmonary fibrosis in systemic sclerosis. Lancet (1991) 1.76
Treatment of systemic vasculitis with pooled intravenous immunoglobulin. Lancet (1991) 1.76
[3H]prazosin binding in the intermediolateral cell column and the effects of iontophoresed methoxamine on sympathetic preganglionic neuronal activity in the anaesthetized cat and rat. Brain Res (1990) 1.75
Tumor necrosis factor alpha suppresses the induction of connective tissue growth factor by transforming growth factor-beta in normal and scleroderma fibroblasts. J Biol Chem (2000) 1.74
Systemic sclerosis associated pulmonary hypertension: improved survival in the current era. Heart (2005) 1.73
Transforming growth factors-beta 1, -beta 2, and -beta 3 stimulate fibroblast procollagen production in vitro but are differentially expressed during bleomycin-induced lung fibrosis. Am J Pathol (1997) 1.70
Locally applied simvastatin promotes fracture healing in ovariectomized rat. Osteoporos Int (2007) 1.68
Evaluation of thirty-one mouse monoclonal antibodies to human IgG epitopes. Hybridoma (1984) 1.67
Anti-RNA polymerases and other autoantibody specificities in systemic sclerosis. Br J Rheumatol (1998) 1.66
Pilot study of anti-thymocyte globulin plus mycophenolate mofetil in recent-onset diffuse scleroderma. Rheumatology (Oxford) (2001) 1.66
The source and role of RANTES in interstitial lung disease. Eur Respir J (1997) 1.62
Typing of Chlamydia trachomatis strains from urine samples by amplification and sequencing the major outer membrane protein gene (omp1). Sex Transm Infect (2001) 1.62
Serological markers in progressive systemic sclerosis: clinical correlations. Ann Rheum Dis (1983) 1.55
Immunohistochemical localization of transforming growth factor-beta 1 in the lungs of patients with systemic sclerosis, cryptogenic fibrosing alveolitis and other lung disorders. Histopathology (1994) 1.54
The use of infra-red thermography in a rheumatology unit. Br J Rheumatol (1990) 1.53
Immunohistological analysis of lung tissue from patients with cryptogenic fibrosing alveolitis suggesting local expression of immune hypersensitivity. Thorax (1985) 1.52
Fibroblast matrix gene expression and connective tissue remodeling: role of endothelin-1. J Invest Dermatol (2001) 1.51
Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis. Eur Respir J (2009) 1.51
Fibrosing alveolitis associated with systemic sclerosis has a better prognosis than lone cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med (1994) 1.49
Challenges in pulmonary fibrosis: 8--The need for an international registry for idiopathic pulmonary fibrosis. Thorax (2008) 1.48
Doxycycline and azithromycin for prevention of chlamydial persistence or recurrence one month after treatment in women. A use-effectiveness study in public health settings. Sex Transm Dis (1998) 1.46
Mannose-binding lectin promoter and structural gene variants in sarcoidosis. Eur J Clin Invest (2000) 1.46
Prediction of five-year survival following presentation with scleroderma: development of a simple model using three disease factors at first visit. Arthritis Rheum (1999) 1.45
Progress in systemic sclerosis: a 10-year perspective. Rheumatology (Oxford) (2009) 1.44
Clearance of inhaled technetium-99m-DTPA as a clinical index of pulmonary vascular disease in systemic sclerosis. Eur Respir J (1999) 1.44
Suppression of endogenous IL-10 gene expression in dendritic cells enhances antigen presentation for specific Th1 induction: potential for cellular vaccine development. J Immunol (2000) 1.42
Observer variation in pattern type and extent of disease in fibrosing alveolitis on thin section computed tomography and chest radiography. Clin Radiol (1994) 1.41
Structural features of interstitial lung disease in systemic sclerosis. Am Rev Respir Dis (1991) 1.41
Antireticulin antibody in systemic sclerosis. Ann Rheum Dis (1990) 1.40
Expression of the neutrophil elastase gene during human bone marrow cell differentiation. J Exp Med (1989) 1.39
Iloprost suppresses connective tissue growth factor production in fibroblasts and in the skin of scleroderma patients. J Clin Invest (2001) 1.39
Variations in histological patterns of interstitial pneumonia between connective tissue disorders and their relationship to prognosis. Histopathology (2004) 1.38
Five patients who developed systemic sclerosis shortly after episodes of physical trauma. J Rheumatol (1996) 1.38
Anti-PL 4 in patients with systemic lupus erythematosus with severe renal and haematological disease. QJM (1997) 1.38
Enzyme immunoassay to determine exposure to Chlamydia pneumoniae (strain TWAR). J Clin Microbiol (1989) 1.37
Pulmonary hypertension in systemic sclerosis: risk factors for progression and consequences for survival. Rheumatology (Oxford) (2001) 1.35
IgG antiendothelial cell autoantibodies from scleroderma patients induce leukocyte adhesion to human vascular endothelial cells in vitro. Induction of adhesion molecule expression and involvement of endothelium-derived cytokines. J Clin Invest (1996) 1.34
Immunocompetent cells in bronchoalveolar lavage reflect the cell populations in transbronchial biopsies in pulmonary sarcoidosis. Am Rev Respir Dis (1985) 1.32
Addition of monoclonal antibodies specific for Rickettsia akari to the rickettsial diagnostic panel. J Clin Microbiol (1988) 1.32
European Scleroderma Study Group to define disease activity criteria for systemic sclerosis. III. Assessment of the construct validity of the preliminary activity criteria. Ann Rheum Dis (2003) 1.32
Lone cryptogenic fibrosing alveolitis: a functional-morphologic correlation based on extent of disease on thin-section computed tomography. Am J Respir Crit Care Med (1997) 1.31
Nonspecific interstitial pneumonia: variable appearance at high-resolution chest CT. Radiology (2000) 1.31
Role of thrombin in pulmonary fibrosis. Lancet (1995) 1.30
Autocrine overexpression of CTGF maintains fibrosis: RDA analysis of fibrosis genes in systemic sclerosis. Exp Cell Res (2000) 1.30
Acidification of phagosomes in murine macrophages: blockage by Nocardia asteroides. J Infect Dis (1986) 1.29
Route of infection that induces a high intensity of gamma interferon-secreting T cells in the genital tract produces optimal protection against Chlamydia trachomatis infection in mice. Infect Immun (1998) 1.29
Clearance of inhaled 99mTc-DTPA predicts the clinical course of fibrosing alveolitis. Eur Respir J (1993) 1.29
N-terminal connective tissue growth factor is a marker of the fibrotic phenotype in scleroderma. QJM (2005) 1.28
In vivo and in vitro activation of alveolar macrophages by recombinant interferon-gamma. J Immunol (1987) 1.28
The predictive value of appearances on thin-section computed tomography in fibrosing alveolitis. Am Rev Respir Dis (1993) 1.28
Serial CT in fibrosing alveolitis: prognostic significance of the initial pattern. AJR Am J Roentgenol (1993) 1.27
Alpha 2-adrenoceptor modulation of nociception in rat spinal cord: location, effects and interactions with morphine. Eur J Pharmacol (1987) 1.25
Mycoplasma contamination of chlamydiae isolated from clinical specimens. APMIS (1994) 1.24
The control of ccn2 (ctgf) gene expression in normal and scleroderma fibroblasts. Mol Pathol (2001) 1.24
High resolution computed tomography as a predictor of lung histology in systemic sclerosis. Thorax (1992) 1.23
HLA-DP allele-specific T cell responses to beryllium account for DP-associated susceptibility to chronic beryllium disease. J Immunol (2001) 1.22
Screening high-risk adolescent males for Chlamydia trachomatis infection. Obtaining urine specimens in the field. Sex Transm Dis (1998) 1.21
Detection and characterization of mouse monoclonal antibodies to epidemic typhus rickettsiae. J Clin Microbiol (1983) 1.21